Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SNSE | Common Stock | Purchase | $14.9K | +752 | +0.02% | $19.75* | 4.69M | Feb 18, 2021 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | This Form 4 is being amended to correct the number of shares purchased. The original Form 4 filed on February 19, 2021, overstated the number of shares purchased. |
F2 | These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares. |